Anti-CTLA4 immunotoxin (scFv)-Mel (CAT#: AGTO-G015M)
This immunotoxin was achieved by conjugating/fusing the Anti-CTLA4 scFv to melittin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to CTLA-4-positive T cells. Once bind, melittin is subsequently incorporated into the cell by receptor-mediated endocytosis and inhibits activities of protein kinase C, Ca2+/calmodulin-dependent protein kinase II, myosin light chain kinase and Na+/K+-ATPase (synaptosomal membrane). It was designed for treatment of Immunosuppressive Agent for Organ Transplant.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4

(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4
Specifications
- Host Species
- Mouse
- Species Reactivity
- Human
- Molecule Class
- scFv-Mel
- Toxin Description
- Melittin is the principal active component of apitoxin (bee venom) and is a powerful stimulator of phospholipase A2. Melittin is a peptide consisting of 26 amino acids with the sequence GIGAVLKVLTTGLPALISWIKRKRQQ. Melittin inhibits protein kinase C, Ca2+/calmodulin-dependent protein kinase II, myosin light chain kinase and Na+/K+-ATPase (synaptosomal membrane) and is a cell membrane lytic factor. Melittin is a small peptide with no disulphide bridge; the N-terminal part of the molecule is predominantly hydrophobic and the C-terminal part is hydrophilic and strongly basic.
- Applications
- This product is suitable for use in cytotoxicity assay, functional assay and immunotherapy.
- Related Disease
- Immunosuppressive Agent for Organ Transplant
Target
- Alternative Names
- CTLA4; cytotoxic T-lymphocyte-associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; Melittin; apitoxin; bee venom; Mel
- Gene ID
- 1493
- UniProt ID
- P16410
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "CTLA4"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-067 | Anti-Human CTLA4 Recombinant Antibody (TAB-067) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-206 | Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG2 |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AGTO-G015M. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, Neut, FuncS
Application: ELISA, Inhib, FC
Application: WB, ELISA
Application: ELISA, IHC, FC, WB, IF, IA
Application: WB, ELISA, IF, FuncS, Apop, BA
Application: ELISA, FuncS, Neut, IF, WB, EM, Inhib, IHC
For Research Use Only. Not For Clinical Use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.